Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO secondary prevention of chemotherapy-induced thrombocytopenia in lymphoma
ChiCTR2400081344Phase 4Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Feb 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) and lymphoma (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoint: Proportion of patients with grade III and IV thrombocytopenia per chemotherapy cycle. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)lymphoma
Beyond the preview
Go deeper on ChiCTR2400081344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081344.